The present invention provides humanized antibodies that immunospecifically recognize human α9 integrin. Some of these antibodies inhibit the biological functions of the α9 integrin, thereby exhibiting therapeutic effects on various disorders or diseases that are associated with α9 integrin, including cancer, e.g., the growth and metastasis of a cancer cell, and inflammatory diseases, e.g., rheumatoid arthritis, osteoarthritis, hepatitis, bronchial asthma, fibrosis, diabetes, arteriosclerosis, multiple sclerosis, granuloma, an inflammatory bowel disease (ulcerative colitis and Crohns disease), an autoimmune disease, and so forth.
